Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Forsta AP Fonden

Forsta AP Fonden trimmed its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXGet Rating) by 25.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 57,500 shares of the pharmaceutical company’s stock after selling 19,800 shares during the quarter. Forsta AP Fonden’s holdings in Vertex Pharmaceuticals were worth $15,006,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. JJJ Advisors Inc. increased its stake in Vertex Pharmaceuticals by 101.5% in the 4th quarter. JJJ Advisors Inc. now owns 133 shares of the pharmaceutical company’s stock valued at $29,000 after buying an additional 67 shares during the period. Trustcore Financial Services LLC increased its stake in Vertex Pharmaceuticals by 53.8% in the 4th quarter. Trustcore Financial Services LLC now owns 143 shares of the pharmaceutical company’s stock valued at $31,000 after buying an additional 50 shares during the period. Crewe Advisors LLC acquired a new position in shares of Vertex Pharmaceuticals during the 4th quarter worth $32,000. Steward Financial Group LLC acquired a new position in shares of Vertex Pharmaceuticals during the 1st quarter worth $34,000. Finally, EverSource Wealth Advisors LLC acquired a new position in shares of Vertex Pharmaceuticals during the 4th quarter worth $36,000. 89.84% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently commented on VRTX. Cowen boosted their price objective on shares of Vertex Pharmaceuticals from $305.00 to $310.00 in a research report on Monday, June 13th. Piper Sandler boosted their price objective on shares of Vertex Pharmaceuticals from $242.00 to $256.00 and gave the stock a “neutral” rating in a research report on Tuesday, July 26th. HC Wainwright boosted their price objective on shares of Vertex Pharmaceuticals from $275.00 to $300.00 and gave the stock a “buy” rating in a research report on Friday. Cantor Fitzgerald began coverage on shares of Vertex Pharmaceuticals in a research report on Tuesday, July 12th. They issued an “overweight” rating and a $365.00 price objective on the stock. Finally, UBS Group boosted their price objective on shares of Vertex Pharmaceuticals from $258.00 to $325.00 in a research report on Wednesday, April 13th. Six analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Vertex Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $289.90.

Vertex Pharmaceuticals Stock Up 4.8 %

VRTX opened at $288.03 on Friday. The firm has a 50 day moving average price of $277.50 and a 200 day moving average price of $260.63. The company has a market cap of $73.67 billion, a PE ratio of 23.28, a price-to-earnings-growth ratio of 2.03 and a beta of 0.45. Vertex Pharmaceuticals Incorporated has a 1 year low of $176.36 and a 1 year high of $296.84. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.60 and a current ratio of 4.75.

Vertex Pharmaceuticals (NASDAQ:VRTXGet Rating) last posted its earnings results on Thursday, August 4th. The pharmaceutical company reported $3.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.12 by $0.48. The firm had revenue of $2.20 billion during the quarter, compared to the consensus estimate of $2.13 billion. Vertex Pharmaceuticals had a net margin of 38.26% and a return on equity of 32.56%. The company’s revenue was up 22.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.80 EPS. Sell-side analysts expect that Vertex Pharmaceuticals Incorporated will post 12.41 earnings per share for the current year.

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, Director Sangeeta N. Bhatia sold 621 shares of the stock in a transaction that occurred on Friday, July 29th. The shares were sold at an average price of $278.77, for a total value of $173,116.17. Following the completion of the sale, the director now owns 5,282 shares of the company’s stock, valued at $1,472,463.14. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CEO Reshma Kewalramani sold 11,689 shares of the stock in a transaction that occurred on Friday, June 24th. The stock was sold at an average price of $291.30, for a total transaction of $3,405,005.70. Following the completion of the transaction, the chief executive officer now directly owns 111,153 shares in the company, valued at approximately $32,378,868.90. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Sangeeta N. Bhatia sold 621 shares of the stock in a transaction that occurred on Friday, July 29th. The shares were sold at an average price of $278.77, for a total value of $173,116.17. Following the transaction, the director now owns 5,282 shares of the company’s stock, valued at $1,472,463.14. The disclosure for this sale can be found here. Insiders sold 162,254 shares of company stock valued at $45,899,243 over the last 90 days. 0.40% of the stock is owned by corporate insiders.

Vertex Pharmaceuticals Company Profile

(Get Rating)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

See Also

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.